Eli Lilly and Company Aktie News

This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented in clinical trials  New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly inten...

Eli Lilly's new U.S. facility will be just the first of four that it plans to build in the country. The company expects to eventually make 100% of drugs for American patients in the U.S.

Even a slow-growing sector can include rapidly growing companies that are putting up big numbers

Eli Lilly is a Strong Buy, driven by exceptional growth in obesity and diabetes drugs Mounjaro and Zepbound, plus pipeline innovation. LLY's diversified business mix, global reach, and proactive U.S. manufacturing investments position it well for regulatory and political developments. Despite sector headwinds and cautious market sentiment, LLY's robust earnings momentum and positive analyst rev...

Eli Lilly signed an agreement with Cipla , allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a separate brand in the country, the companies said on Thursday.

Sold 6,430 shares of Eli Lilly and Company; estimated transaction value ~$4.78 million Post-trade holding: 61,292 shares valued at $46.77 million Position now 1% of fund AUM, which places it outside the fund's top five holdings

Eli Lilly is expected to present third-quarter results on Oct. 30 after the market opens. Wall Street analysts will be looking closely at sales growth for Mounjaro and Zepbound.

But if you have $1,000 to put into the market, there are several quality names that offer significant upside even though—in some cases—they've outperformed the market in 2025. In other words, if you're looking for long-term growth, there are opportunities available that will allow you to generate a solid return without the volatility that can come with low-priced stocks.